таблица по беременности на определение пола ребенка
Главное меню:
Интересное
таблица по беременности на определение пола ребенка, XYWAV for Idiopathic Hypersomnia | XYWAV® IH, Xywav: Uses, Dosage, Side Effects, Warnings - Drugs.com, FDA-Approved Treatment for Idiopathic Hypersomnia | XYWAV HCP, Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing , How Xywav Works, And Other Questions Answered - GoodRx, Jazz Presents New Data on Xywav's Impact on Narcolepsy and IH | Sleep , Idiopathic Hypersomnia Symptoms and Treatment | XYWAV® IH.
CategoryMedicationsMechanism of ActionCommon IndicationsStimulantsModafinil, ArmodafinilPromotes wakefulness through dopamine pathwaysNarcolepsy, Sleep Apnea, Shift Work Disorder MethylphenidateCNS stimulant that increases dopamine and norepinephrineAttention-Deficit/Hyperactivity Disorder (ADHD), Narcolepsy Amphetamine saltsEnhances release of dopamine and norepinephrineADHD, NarcolepsyNon-Stimulant Wakefulness AgentsSolriamfetolDopamine and norepinephrine reuptake inhibitorNarcolepsy, Sleep Apnea PitolisantHistamine H3 receptor antagonistNarcolepsyOther MedicationsSodium oxybateGABA receptor modulator, improves sleep architectureNarcolepsy with Cataplexy AntidepressantsModulate serotonin and norepinephrineDepression-related EDS, Excessive daytime sleepiness Sleep inertia Severe grogginess or confusion when waking up regardless of how much sleep you get or how many alarms you set—feeling disoriented, irritable, or even clumsy when waking up and for hours afterwards, Xywav is used for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy, and idiopathic hypersomnia (IH). Includes Xywav side effects, interactions and indications..
The safety and effectiveness of XYWAV for the treatment of cataplexy or excessive daytime sleepiness in pediatric patients 7 years of age and older with narcolepsy have been established., Xywav is the only low-sodium oxybate approved by the U.S. Food and Drug Administration for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy and for adults with idiopathic hypersomnia. The Xywav label recommends a nightly dose of 6-9 grams per night., Xywav was originally FDA-approved in 2002 to treat excessive daytime sleepiness (EDS) and cataplexy (sudden muscle weakness triggered by strong emotions) in people at least 7 years old who have narcolepsy. It became FDA-approved for IH in adults in 2021. Xywav is unique because it’s the only medication that’s specifically FDA-approved for IH., Notably, these DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) data show prospective improvements on excessive daytime sleepiness, as well as key polysomnography outcomes of sleep disruption, among adults with narcolepsy treated with Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution., XYWAV is the first and only FDA-approved medication to treat IH in adults. XYWAV has been studied across multiple symptoms of IH, such as excessive daytime sleepiness, sleep inertia, cognitive impairment, and long sleep time., Management of excessive daytime sleepiness (EDS) includes both pharmacologic and nonpharmacologic options, depending on its underlying cause..